Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

U.S. to raise age limit for vaping to 21

The United States plans to raise the age limit for vaping to 21, U.S. President Donald Trump said.

Read More »

44 Life Sciences Associations Sign Letter Opposing Pelosi Drug Pricing Plan

Life sciences organizations are marshaling their forces in opposition to Nancy Pelosi’s drug pricing reform bill.

Read More »

Pfizer Looks to Fill Void for Chemo Drug After Teva Discontinues Generic Version

Doctors are warning of a potential shortage and rationing began for vincristine as Pfizer represents the only manufacturer for the chemotherapy drug.

Read More »

PhRMA Predicts Dire Consequences for Pharma Industry if Pelosi Plan Passes

PhRMA CEO Stephen Ubl said House Speaker Nancy Pelosi’s plan would be “devastating” to the industry.

Read More »

U.S. prices for multiple sclerosis drugs are on the rise

A U.S. study suggests that annual costs of disease modifying treatments for multiple sclerosis more than quadrupled from 2006 to 2016 as several new, costly medicines entered the market.

Read More »

Novo Nordisk and Mylan Battle Over Generic Versions of Victoza

Denmark’s Novo Nordisk filed a lawsuit in a Delaware district court against generic drugmaker Mylan.

Read More »

Roche cancer treatment priced at $17,050 a month, lower than rival Vitrakvi

Roche Holding AG priced the company’s personalized cancer treatment Rozlytrek at about $17,050 per month, nearly half of the monthly price of a rival drug from Bayer AG and Eli Lilly and Co. that was approved during 2018.

Read More »

Report: Projected Sales of 10 Top-Selling Drugs Through 2024

A report by Evaluate Pharma estimates prescription drug sales will hit $1.18 trillion by 2024, driven by cell and gene therapies.

Read More »

Senators Urge FDA to Take Action Against AveXis

Days after the U.S. FDA revealed data manipulation was involved in the early studies of Novartis’ multi-million dollar gene therapy for SMA, U.S. Senate members demanded the regulatory agency take action against AveXis, the company that developed Zolgensma.

Read More »

Top 200 Medicines Annual Report 2019: The king of medicines

Humira’s dominance continues as the world’s top-selling prescription product as the biologic therapy is the first drug to exceed $20 billion in annual global sales.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom